CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy)(CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy)) - 药物靶点：CD19 x CD20_在研适应症：难治性慢性淋巴细胞白血病，复发性弥漫性大B细胞淋巴瘤，难治性弥漫性大 B 细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名

CD19/CD20 chimeric antigen receptor (CAR) T-cells

靶点

CD19 x CD20

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、细胞替代物

+ [1]

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

难治性慢性淋巴细胞白血病复发性弥漫性大B细胞淋巴瘤难治性弥漫性大 B 细胞淋巴瘤+ [8]

非在研适应症-

原研机构

The Parker Institute For Cancer Immunotherapy初创企业

在研机构

Jonsson Comprehensive Cancer Center

The Parker Institute For Cancer Immunotherapy初创企业

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy) 相关的临床试验

ACTRN12619001656123 / Not yet recruiting临床1期IIT

Clarifying the role of early application of CAR T cells in Primary refractory and early relapsed diffuse large B cell lymphoma patients.

开始日期2020-06-01

申办/合作机构

Australasian Leukaemia & Lymphoma Group

NCT04007029 / Recruiting临床1期IIT

Study of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CD20 - Cluster of Differentiation Antigen 20)

This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic lymphocytic leukemia that has come back (recurrent) or has not responded to treatment (refractory). In CAR-T cell therapy, a patient's white blood cells (T cells) are changed in the laboratory to produce an engineered receptor that allows the T cell to recognize and respond to CD19 and CD20 proteins. CD19 and CD20 are commonly found on non-Hodgkin?s B-cell lymphoma and chronic lymphocytic leukemia cells. Chemotherapy drugs such as fludarabine phosphate and cyclophosphamide can control cancer cells by killing them, by preventing their growth, or by stopping them from spreading. Combining CD19/CD20 CAR-T cells and chemotherapy may help treat patients with recurrent or refractory B-cell lymphoma or chronic lymphocytic leukemia.

开始日期2019-10-04

申办/合作机构

Jonsson Comprehensive Cancer Center

[+1]

100 项与 CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy) 相关的临床结果

登录后查看更多信息

100 项与 CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy) 相关的转化医学

登录后查看更多信息

100 项与 CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy) 相关的专利（医药）

登录后查看更多信息

566

项与 CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy) 相关的文献（医药）

2024-09-01·Journal for ImmunoTherapy of Cancer

Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy

Article

作者: Thieblemont, Catherine ; Carpentier, Antoine F ; Azoulay, Elie ; Bouvier, Amélie ; Allain, Vincent ; Ursu, Renata ; Cuffel, Alexis ; Di Blasi, Roberta ; Larue, Marion ; Caillat-Zucman, Sophie ; Maillard, Alexis

Immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant cause of morbidity associated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy. Early prediction of patients who will develop ICANS would be crucial to better guide individualized management of high-risk patients, but specific predictive markers are still missing. Serum neurofilament light chain (NfL) levels are a sensitive indicator of neuroaxonal injury in neurological diseases. Elevated NfL levels at the time of CAR T-cell infusion have been associated with the severity of ICANS, but their utility for earlier identification of patients with subclinical neurological damage has not been evaluated.We studied all consecutive adult patients who received commercial CAR T cells for relapsed/refractory B-cell lymphomas at Saint-Louis Hospital between January 2019 and February 2023. Patients with pre-existing or current neurological disease were excluded. NfL levels were quantified in frozen serum collected at the time of the decision to treat (ie, the day of leukapheresis) and at the time of treatment (ie, the day of infusion).Of the 150 study patients, 28% developed ICANS of any grade, including 15.3% of grade 2–4. Receiving a CAR construct with a CD28 domain (58% of patients) was the strongest predictor of grade 2–4 ICANS. Serum NfL levels were significantly higher in patients with grade 2–4 ICANS than in those with grade 0–1 ICANS, both at the time of leukapheresis and infusion. In multivariate models, NfL above the cut-off value was independently associated with grade 2–4 ICANS at leukapheresis (NfL>75 pg/mL, OR 4.2, 95% CI 1.2 to 14.2, p=0.022) and infusion (NfL>58 pg/mL, OR 4.3, 95% CI 1.3 to 13.7, p=0.015).In conclusion, high NfL levels at the time of the decision to proceed with CAR T-cell manufacturing may represent an early surrogate of underlying loss of neuroaxonal integrity that increases the risk of subsequent neurotoxicity. Incorporating NfL levels into the decision-making process based on each patient’s risk profile could help determine the appropriate CAR product when possible, and guide the prophylactic or therapeutic management of ICANS.

2024-07-01·Clinical and Translational Radiation Oncology

Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report

Article

作者: Pursley, Jennifer ; Patel, Chirayu G ; Ababneh, Hazim S ; Connor Johnson, P

Radiation therapy (RT) is utilized as a bridging strategy for patients with aggressive B-cell lymphoma prior to CD19-targeted chimeric antigen receptor (CAR T)-cell therapy. RT has been shown to provide local control without exacerbating the toxicities associated with subsequent CAR T-cell infusion. However, a consensus on the optimal radiation dose and fractionation for bridging purposes has yet to be established. We present a case of a patient with relapsed aggressive B-cell lymphoma who underwent bridging adaptive RT on a CT-linac prior to receiving CAR T-cell therapy. At month 6 post-CAR T infusion, the patient demonstrates no signs of disease recurrence or relapse, nor any unexpected toxicities attributable to the combined treatment. This underscores the feasibility and success of this innovative approach in treating lymphoma patients undergoing CAR T-cell therapy.

2024-06-01·Oncology and Therapy

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) FL with CAR-T Cell Therapy: A Vodcast and Case Example

Article

作者: Hübel, Kai

Follicular lymphoma (FL) is often considered a chronic disease with frequent relapses, shortening both response duration and survival after every relapse. Selecting the most appropriate therapy at the right time within the treatment timeline is key to optimize outcomes. The aim of this vodcast, featuring Dr. Kai Hübel, is to outline the severity of FL by referring to a patient case as well as highlight chimeric antigen receptor (CAR)-T cells as an effective therapy in relapsed/refractory (r/r) FL. The patient was in their early 50s, diagnosed with FL in the early 2010s and presented with a third relapse. The patient complained of night sweats and fatigue but was still capable of self-care (Eastern Cooperative Oncology Group Performance Status Scale 2). The patient received eight cycles of rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP), followed by irradiation and rituximab maintenance (first-line) and then received rituximab 4 × weekly, followed by rituximab maintenance (second-line). The patient relapsed during rituximab maintenance; the patient was rituximab refractory. The patient received six cycles of bendamustine/obinutuzumab followed by obinutuzumab maintenance. The patient relapsed during obinutuzumab maintenance, achieved a partial remission after irradiation and was switched to R/lenalidomide. Due to several high-risk features, CAR-T cell therapy was initiated. Dr. Hubel underlines how earlier treatment with CAR-T cell therapy would have been beneficial for this patient. Results of the ELARA trial as well as comparative studies have shown tisagenlecleucel to be more effective than standard of care in extensively pretreated r/r FL, including high-risk patients. In conclusion, CAR-T cell therapy is a promising therapy option for patients with multiply r/r FL. A vodcast feature is available for this article.

100 项与 CD19/CD20 CAR-T Cells(The Parker Institute For Cancer Immunotherapy) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性弥漫性大B细胞淋巴瘤	临床1期	美国	The Parker Institute For Cancer Immunotherapy初创企业	2019-10-04
复发性弥漫性大B细胞淋巴瘤	临床1期	美国	Jonsson Comprehensive Cancer Center	2019-10-04
复发性套细胞淋巴瘤	临床1期	美国	The Parker Institute For Cancer Immunotherapy初创企业	2019-10-04
复发性套细胞淋巴瘤	临床1期	美国	Jonsson Comprehensive Cancer Center	2019-10-04
复发性原发性纵隔大B细胞淋巴瘤	临床1期	美国	The Parker Institute For Cancer Immunotherapy初创企业	2019-10-04
复发性原发性纵隔大B细胞淋巴瘤	临床1期	美国	Jonsson Comprehensive Cancer Center	2019-10-04
复发性慢性淋巴细胞白血病	临床1期	美国	Jonsson Comprehensive Cancer Center	2019-10-04
复发性慢性淋巴细胞白血病	临床1期	美国	The Parker Institute For Cancer Immunotherapy初创企业	2019-10-04
难治性小淋巴细胞淋巴瘤	临床1期	美国	Jonsson Comprehensive Cancer Center	2019-10-04
难治性小淋巴细胞淋巴瘤	临床1期	美国	The Parker Institute For Cancer Immunotherapy初创企业	2019-10-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04007029 (AACR2023) 人工标引	临床1期	难治性非霍奇金淋巴瘤	11	CD19/CD20 CAR-T Cells	(鬱製積糧夢淵築獵廠膚) = Neurotoxicity was not observed 衊膚鑰網顧繭鹽網齋範 (選鏇顧齋壓網顧淵積淵 ) 更多	积极	2023-04-14
NCT04007029 (ASCO2022) 人工标引	临床1期	非霍奇金淋巴瘤	9	Chimeric Antigen Receptor T-Cell Therapy+Cyclophosphamide+Fludarabine Phosphate+Tocilizumab	(齋顧積艱蓋鹽範壓窪醖) = 鏇糧壓鬱範製鑰淵願選鏇淵觸憲襯範餘壓顧選 (鹽鹽鏇繭網鑰繭窪網顧 ) 更多	积极	2022-06-02